Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Gangliosides
  • Neoplasm, Residual
  • Neuroblastoma

abstract

  • Despite high-risk nature of stage 4 NB, long-term remission without autologous (A)BMT can be achieved with 3F8 treatment. Its side effects were short-lived and manageable. The potential benefits of 3F8 in consolidating remission warrant further investigations.

publication date

  • September 1998

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9738575

Additional Document Info

start page

  • 3053

end page

  • 60

volume

  • 16

number

  • 9